Difference between revisions of "Malignant solid neoplasm, SMO-mutated or PTCH-1-mutated (Hedgehog)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200") |
m |
||
Line 23: | Line 23: | ||
====Eligibility criteria==== | ====Eligibility criteria==== | ||
*SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations | *SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations | ||
− | ==== | + | ====Targeted therapy==== |
*[[Vismodegib (Erivedge)]] 150 mg PO once per day | *[[Vismodegib (Erivedge)]] 150 mg PO once per day | ||
Revision as of 15:08, 24 August 2020
1 regimens on this page
1 variants on this page
|
All lines of therapy
Vismodegib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Hainsworth et al. 2018 (MyPathway) | Phase IIa |
Eligibility criteria
- SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations
Targeted therapy
- Vismodegib (Erivedge) 150 mg PO once per day
Continued indefinitely
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed